|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 10 November 2021, 16:21. The announcement is not marked as price sensitive, and is 27 page(s) in length and 1.06MB in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.456% short sold according to ASIC data. It was ranked the 293rd most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Invex to Present at Bell Potter Healthcare Conference | 10 November 2021, 16:21 |
| Notice of Webinar & Investor Presentation | 4 November 2021, 14:41 |
| Global Phase 3 Trial of Presendin to Launch in Q4 2021 | 4 November 2021, 9:12 |
| Notice of Annual General Meeting/Proxy Form | 25 October 2021, 9:38 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 